[FORM 8-K CURRENT REPORTte of Report (Date of earliest event reported):February 24, 2010 NF ENERGYVINGRPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction oforporation) (IRS Employer Identification No.) 21 - Jia Bei Si Dong Road, Tie Xi Qu Shenyang, P.R. China 110021 (Zipde) (8624) 2560-9750 (Former Name or Formerdress, if Changed Since Last Report)]
[Skystar to Present at Upcoming Investornferences XI'AN, CHINA March 2, 2010ystar Bio-Pharmaceuticalmpany Rodman & Renshaw Annual China Investmentnference at The Regent Hotel in Beijing, China on March 8, 2010 at 2:25pm Beijing time (1:25am Eastern time); nd Roth 22 http://www.ir-site.com/skystar/events.asp An audio and slide webcast of each presentation will be available under the Events and]
[Skystar to Present at Upcoming Investornferences XI'AN, CHINA March 2, 2010ystar Bio-Pharmaceuticalmpany Rodman & Renshaw Annual China Investmentnference at The Regent Hotel in Beijing, China on March 8, 2010 at 2:25pm Beijing time (1:25am Eastern time); nd Roth 22 http://www.ir-site.com/skystar/events.asp An audio and slide webcast of each presentation will be available under the Events and]
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
[NF Energy Saving Corporation Issues Preliminary 2009 Results The Company Expects 28% Revenue Growth and 250% EPS Growth Year over Year SHENYANG, China, February 25, 2010 For the year ended December 31, 2009, the Company anticipates it will record revenues in the range of $20 to $21 million, which represents an approximate increase of 28% when compared to $15.83 of]
[NF Energy Saving Corporation Issues Preliminary 2009 Results The Company Expects 28% Revenue Growth and 250% EPS Growth Year over Year SHENYANG, China, February 25, 2010 For the year ended December 31, 2009, the Company anticipates it will record revenues in the range of $20 to $21 million, which represents an approximate increase of 28% when compared to $15.83 of]
[NF Energyvingrporation Issues Preliminary 2009 Results Thempany Expects 28% Revenue Growth and 250% EPS Growth Year over Year SHENYANG, China, February 25, 2010 For the year ended December 31, 2009, thempany anticipates it will record revenues in the range of $20 to $21 million, which represents an approximaterease of 28% whenmpared to $15.83 of revenues]
